TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
2.080
0.00 (0.00%)
Aug 13, 2026, 1:32 PM EDT - Market open
TherapeuticsMD Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3.27 | 3.02 | 1.76 | 1.3 | 69.96 | 2.57 | |
Revenue Growth | 27.78% | 71.61% | 35.25% | -98.14% | 2619.12% | -96.03% |
Cost of Revenue | - | - | - | - | 1.4 | 1.4 |
Gross Profit | 3.27 | 3.02 | 1.76 | 1.3 | 68.57 | 1.17 |
Selling, General & Admin | 6.74 | 6.85 | 6.1 | 8.9 | 56.71 | 80.75 |
Depreciation & Amortization Expenses | 0.38 | 0.38 | 0.51 | 0.92 | 1.19 | - |
Other Operating Expenses | 0.22 | 0.18 | 1.27 | 9.83 | 9.47 | 80.75 |
Total Operating Expenses | 7.34 | 7.41 | 7.87 | 19.65 | 67.38 | 161.5 |
Operating Income | -1.68 | -4.39 | -6.11 | -8.52 | 1.19 | -79.58 |
Interest Income | 3.43 | 3.74 | 3.77 | 0.78 | -0.12 | - |
Interest Expense | 0 | - | - | - | - | - |
Other Non-Operating Income (Expense) | 2.72 | 3.74 | 3.77 | 0.78 | -0.12 | 0.54 |
Total Non-Operating Income (Expense) | 6.16 | 7.47 | 7.54 | 1.56 | -0.23 | 0.54 |
Pretax Income | -0.26 | -0.65 | -2.34 | -7.74 | 1.07 | -79.31 |
Provision for Income Taxes | 0.03 | - | -0.03 | -0.04 | - | - |
Net Income | -0.3 | -0.65 | -2.31 | -7.7 | 1.07 | -79.31 |
Earnings From Discontinued Operations | 0.08 | 0.08 | 0.13 | -2.58 | 110.92 | -93.11 |
Net Income to Common | -0.22 | -0.57 | -2.18 | -10.28 | 112 | -172.42 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 12 | 12 | 12 | 10 | 9 | 8 |
Shares Outstanding (Diluted) | 12 | 12 | 12 | 10 | 9 | 8 |
Shares Change | 0.53% | 0.32% | 10.45% | 11.48% | 17.66% | 44.39% |
EPS (Basic) | -0.03 | -0.05 | -0.19 | -0.74 | 12.41 | -9.96 |
EPS (Diluted) | -0.03 | -0.05 | -0.19 | -0.74 | 11.96 | -9.96 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 3.1 | 2.45 | 1.17 | -23.08 | 9.36 | -55.17 |
Free Cash Flow Growth | 201.85% | 109.74% | - | - | - | - |
Free Cash Flow Per Share | 0.27 | 0.21 | 0.10 | -2.21 | 1.00 | -6.93 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 98.00% | 45.51% |
Operating Margin | -51.31% | -145.27% | -347.08% | -654.61% | 1.70% | -3092.77% |
Profit Margin | -9.02% | -21.61% | -131.29% | -591.32% | 1.54% | -3082.20% |
FCF Margin | 94.71% | 81.20% | 66.44% | -1772.73% | 13.38% | -2144.07% |
EBITDA | -1.3 | -4.01 | -5.6 | -7.6 | 2.38 | -78.84 |
EBITDA Margin | -39.63% | -132.56% | -318.17% | -583.79% | 3.41% | -3064.17% |
EBIT | -1.68 | -4.39 | -6.11 | -8.52 | 1.19 | -79.58 |
EBIT Margin | -51.31% | -145.27% | -347.08% | -654.61% | 1.70% | -3092.77% |
Effective Tax Rate | -12.17% | 0.00% | 1.32% | 0.56% | 0.00% | 0.00% |